Key result
Phosphoramidon and pepstatin A significantly reduced the secretion of endothelin-1 from cultured human umbilical vein endothelial cells (P<0.05).
Population
Cultured first-passage human umbilical vein endothelial cells
Comparison
Phosphoramidon (1 × 10−4 mol/l) and pepstatin A vs Controls
Design
Preclinical
Follow-up
12 h
Authors
Loading...
Supports further investigation of pepstatin A-sensitive enzymes for endothelin-1 modulation; leaves open therapeutic potential in cardiovascular disease.
p-value: p=<0.05
Pepstatin A-sensitive enzymes may be potential targets to reduce the generation of vasoconstrictive endothelin-1 in cardiovascular diseases.
Plumpton et al. (1994) studied this question. Phosphoramidon and pepstatin A vs. Controls was evaluated on Secretion of endothelin-1 and big endothelin-1 (p=<0.05). Phosphoramidon and pepstatin A significantly reduced the secretion of endothelin-1 from cultured human umbilical vein endothelial cells (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: